COVID-19
The NanoDx™ System for SARS-CoV-2 uses a patented nanosensor technology platform to detect the presence of SARS-CoV-2 in a nasal, throat, or saliva sample.
The NanoDx™ System for SARS-CoV-2
- Addresses existing diagnostic challenges by providing a rapid, qualitative assessment of COVID-19 from a nasal, throat, or saliva sample
- Measurement of SARS-CoV-2 antigen in patient specimen sample
- The presence or absence of the SARS-CoV-2 is measured and a “Positive” or “Negative” result is displayed
- Addresses existing diagnostic challenges by providing a rapid, qualitative assessment of COVID-19 from a nasal, throat, or saliva sample
- Measurement of SARS-CoV-2 antigen in patient specimen sample
- The presence or absence of the SARS-CoV-2 is measured and a “Positive” or “Negative” result is displayed
*The NanoDxTM System has not been evaluated by the FDA or other regulatory agencies.
